Immune-Related Adverse Effects of Cancer Immunotherapy— Implications for Rheumatology

Rheumatic Disease Clinics of North America

Volumn 43, Issue 1, 2017, Pages 65-78

  Cappelli, Laura C ^a   Shah, Ami A ^a   Bingham, Clifton O ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Arthritis; Immune checkpoint inhibitors; Immune related adverse events; Malignancy; Sicca syndrome

Indexed keywords

AMP 224; ANTINEOPLASTIC AGENT; ATEZOLIZUMAB; AVELUMAB; BEVACIZUMAB; BMS 986016; CANCER VACCINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DACARBAZINE; DOCETAXEL; DURVALUMAB; ENOBLITUZUMAB; HYDROXYCHLOROQUINE; IMMUNE CHECKPOINT INHIBITOR; IMMUNOMODULATING AGENT; IMP 321; IPILIMUMAB; MBG 453; MGD 009; NIVOLUMAB; NONSTEROID ANTIINFLAMMATORY AGENT; PEMBROLIZUMAB; PEPTIDE VACCINE; PIDILIZUMAB; PREDNISONE; RECOMBINANT INTERLEUKIN 2; SARGRAMOSTIM; TICILIMUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; URELUMAB;

ADVERSE DRUG REACTION; ARTHRALGIA; ARTHRITIS; CANCER IMMUNOTHERAPY; CLINICAL FEATURE; DERMATOMYOSITIS; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG WITHDRAWAL; DRY EYE; GIANT CELL ARTERITIS; HODGKIN DISEASE; HUMAN; IMMUNE RELATED ADVERSE EVENT; IMMUNOPATHOLOGY; INCIDENCE; KIDNEY CARCINOMA; LUPUS ERYTHEMATOSUS NEPHRITIS; MALIGNANT NEOPLASM; MELANOMA; METASTATIC MELANOMA; MUSCLE WEAKNESS; MUSCULOSKELETAL DISEASE; MYALGIA; MYOSITIS; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; RHEUMATIC POLYMYALGIA; RHEUMATOID ARTHRITIS; RHEUMATOLOGIST; RHEUMATOLOGY; SJOEGREN SYNDROME; T LYMPHOCYTE ACTIVATION; TENOSYNOVITIS; TRANSITIONAL CELL CARCINOMA; TUMOR IMMUNITY; VASCULITIS; XEROSTOMIA; AUTOIMMUNE DISEASE; CHEMICALLY INDUCED; COMPLICATION; DISEASE COURSE; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS;

ARTHRITIS; AUTOIMMUNE DISEASES; DISEASE PROGRESSION; HUMANS; IMMUNOTHERAPY; MYOSITIS; NEOPLASMS; RHEUMATOLOGY; SJOGREN'S SYNDROME; VASCULITIS;

EID: 85001610237     PISSN: 0889857X     EISSN: 15583163     Source Type: Journal    
DOI: 10.1016/j.rdc.2016.09.007     Document Type: Review

References (54)

1. 1 Shah, A.A., Casciola-Rosen, L., Rosen, A., Review: cancer-induced autoimmunity in the rheumatic diseases. Arthritis Rheumatol 67:2 (2015), 317–326.
2. 2 Schreiber, R.D., Old, L.J., Smyth, M.J., Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331:6024 (2011), 1565–1570.
3. 3 Rosenberg, S.A., IL-2: the first effective immunotherapy for human cancer. J Immunol 192:12 (2014), 5451–5458.
4. 4 Pardoll, D.M., The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:4 (2012), 252–264.
5. 5 Brahmer, J.R., Hammers, H., Lipson, E.J., Nivolumab: targeting PD-1 to bolster antitumor immunity. Future Oncol 11:9 (2015), 1307–1326.
6. 6 Topalian, S.L., Drake, C.G., Pardoll, D.M., Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27:4 (2015), 450–461.
7. 7 Buchbinder, E.I., McDermott, D.F., Cytotoxic T-lymphocyte antigen-4 blockade in melanoma. Clin Ther 37:4 (2015), 755–763.
8. 8 Ivashko, I.N., Kolesar, J.M., Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma. Am J Health Syst Pharm 73:4 (2016), 193–201.
9. 9 Brahmer, J., Reckamp, K.L., Baas, P., et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373:2 (2015), 123–135.
10. 10 Motzer, R.J., Escudier, B., McDermott, D.F., et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373:19 (2015), 1803–1813.
11. 11 Postow, M.A., Chesney, J., Pavlick, A.C., et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372:21 (2015), 2006–2017.
12. 12 NIH. ClinialTrials.gov website. 2015. Available at: https://clinicaltrials.gov/. Accessed December 27, 2015.
13. 13 Nghiem, P.T., Bhatia, S., Lipson, E.J., et al. PD-1 Blockade with pembrolizumab in advanced Merkel-cell carcinoma. N Engl J Med 374 (2016), 2542–2552.
14. 14 Le, D.T., Uram, J.N., Wang, H., et al. PD-1 Blockade in tumors with mismatch-repair deficiency. N Engl J Med 372:26 (2015), 2509–2520.
15. 15 Weber, J.S., Yang, J.C., Atkins, M.B., et al. Toxicities of immunotherapy for the practitioner. J Clin Oncol 33:18 (2015), 2092–2099.
16. 16 Naidoo, J., Page, D.B., Li, B.T., et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 26:12 (2015), 2375–2391.
17. 17 Spain, L., Diem, S., Larkin, J., Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev 44 (2016), 51–60.
18. 18 Robert, C., Schachter, J., Long, G.V., et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372:26 (2015), 2521–2532.
19. 19 Wolchok, J.D., Neyns, B., Linette, G., et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 11:2 (2010), 155–164.
20. 20 Hodi, F.S., O'Day, S.J., McDermott, D.F., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:8 (2010), 711–723.
21. 21 Postow, M.A., Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book 35 (2015), 76–83.
22. 22 Weber, J.S., Kahler, K.C., Hauschild, A., Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 30:21 (2012), 2691–2697.
23. 23 Larkin, J., Chiarion-Sileni, V., Gonzalez, R., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:1 (2015), 23–34.
24. 24 Kwon, E.D., Drake, C.G., Scher, H.I., et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 15:7 (2014), 700–712.
25. 25 Gibney, G.T., Kudchadkar, R.R., DeConti, R.C., et al. Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma. Clin Cancer Res 21:4 (2015), 712–720.
26. 26 Brahmer, J.R., Drake, C.G., Wollner, I., et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28:19 (2010), 3167–3175.
27. 27 Woodworth, T., Furst, D.E., Alten, R., et al. Standardizing assessment and reporting of adverse effects in rheumatology clinical trials II: the rheumatology common toxicity criteria v.2.0. J Rheumatol 34:6 (2007), 1401–1414.
28. 28 Bronstein, Y., Ng, C.S., Hwu, P., et al. Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy. AJR Am J Roentgenol 197:6 (2011), W992–W1000.
29. 29 Capozzi, V., Makhoul, S., Aprea, E., et al. PTR-MS characterization of VOCs associated with commercial aromatic bakery yeasts of wine and beer origin. Molecules, 21(4), 2016, 483.
30. 30 Motzer, R.J., Rini, B.I., McDermott, D.F., et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol 33:13 (2015), 1430–1437.
31. 31 Le, D.T., Lutz, E., Uram, J.N., et al. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J Immunother 36:7 (2013), 382–389.
32. 32 Hodi, F.S., Lee, S., McDermott, D.F., et al. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. JAMA 312:17 (2014), 1744–1753.
33. 33 Hersh, E.M., O'Day, S.J., Powderly, J., et al. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma. Invest New Drugs 29:3 (2011), 489–498.
34. 34 Borghaei, H., Paz-Ares, L., Horn, L., et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373:17 (2015), 1627–1639.
35. 35 Chan, M.M., Kefford, R.F., Carlino, M., et al. Arthritis and tenosynovitis associated with the anti-PD1 antibody pembrolizumab in metastatic melanoma. J Immunother 38:1 (2015), 37–39.
36. 36 de Velasco, G., Bermas, B., Choueiri, T.K., Auto-immune arthropathy and uveitis as complications from PD-1 inhibitor. Arthritis Rheumatol 68 (2016), 556–557.
37. 37 Sheik Ali, S., Goddard, A.L., Luke, J.J., et al. Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade. JAMA Dermatol 151:2 (2015), 195–199.
38. 38 Yoshioka, M., Kambe, N., Yamamoto, Y., et al. Case of respiratory discomfort due to myositis after administration of nivolumab. J Dermatol 42:10 (2015), 1008–1009.
39. 39 Khoja, L., Maurice, C., Chappell, M., et al. Eosinophilic fasciitis and acute encephalopathy toxicity from pembrolizumab treatment of a patient with metastatic melanoma. Cancer Immunol Res 4 (2016), 175–178.
40. 40 Goldstein, B.L., Gedmintas, L., Todd, D.J., Drug-associated polymyalgia rheumatica/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of ctla-4. Arthritis Rheumatol 66:3 (2014), 768–769.
41. 41 Manusow, J.S., Khoja, L., Pesin, N., et al. Retinal vasculitis and ocular vitreous metastasis following complete response to PD-1 inhibition in a patient with metastatic cutaneous melanoma. J Immunother Cancer, 2(1), 2014, 41.
42. 42 Minor, D.R., Bunker, S.R., Doyle, J., Lymphocytic vasculitis of the uterus in a patient with melanoma receiving ipilimumab. J Clin Oncol, 31(20), 2013, e356.
43. 43 Fadel, F., El Karoui, K., Knebelmann, B., Anti-CTLA4 antibody-induced lupus nephritis. N Engl J Med 361:2 (2009), 211–212.
44. 44 Iwama, S., De Remigis, A., Callahan, M.K., et al. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med, 6(230), 2014, 230ra245.
45. 45 Klair, J.S., Girotra, M., Hutchins, L.F., et al. Ipilimumab-induced gastrointestinal toxicities: a management algorithm. Dig Dis Sci 61 (2016), 2132–2139.
46. 46 Turesson, C., Matteson, E.L., Malignancy as a comorbidity in rheumatic diseases. Rheumatology (Oxford) 52:1 (2013), 5–14.
47. 47 Stone, J.H., Holbrook, J.T., Marriott, M.A., et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum 54:5 (2006), 1608–1618.
48. 48 Johnston, R.L., Lutzky, J., Chodhry, A., et al. Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab. Dig Dis Sci 54:11 (2009), 2538–2540.
49. 49 Gogas, H., Ioannovich, J., Dafni, U., et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 354:7 (2006), 709–718.
50. 50 Gielisse, E.A., de Boer, N.K., Ipilimumab in a patient with known Crohn's disease: to give or not to give?. J Crohns Colitis, 8(12), 2014, 1742.
51. 51 Bostwick, A.D., Salama, A.K., Hanks, B.A., Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis. J Immunother Cancer, 3, 2015, 19.
52. 52 Johnson, D.B., Sullivan, R.J., Ott, P.A., et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol 2 (2016), 234–240.
53. 53 Joseph, C.G., Darrah, E., Shah, A.A., et al. Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science 343:6167 (2014), 152–157.
54. 54 Shah, A.A., Rosen, A., Hummers, L., et al. Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies. Arthritis Rheum 62:9 (2010), 2787–2795.